Study outcomes at endpoint (3 months)
| Control group (N=101) | Intervention group (N=85) | Group difference (95% CI) | |
| Primary outcome | |||
| Adherent (N, %) | 55 (54) | 52 (63) | −8 (−22 to 6) |
| Secondary medication outcomes | |||
| CQR continuous (mean, SD) | 75±12 | 73±11 | 2.2 (−1.1 to 5.5) |
| Pill count in percentage† (mean, SD) | 95±16 | 97±8 | −2.3 (−9.7 to 5.1) |
| BMQ-Specific NCD score (mean, SD) | 4.8±4.2 | 5.3±4.7 | −0.5 (−1.8 to 0.8) |
| Secondary clinical outcomes | |||
| RADAI score (median, IQR) | 2.5 (1.2–4.0) | 2.5 (1.5–4.2) | 0.0 (−0.8 to 0.8) |
| HAQ score (median, IQR) | 0.8 (0.3–1.4) | 0.6 (0.3–1.4) | −0.1 (−0.5 to 0.2) |
*Percentage of the total number of participants excluding missing data.
†N=21 for the control group and N=24 for the intervention group .
BMQ NCD, Beliefs about Medication Questionnaire necessity-concerns differential; CQR, Compliance Questionnaire on Rheumatology; HAQ, Health Assessment Questionnaire; IQR, interquartile range; n, number; RADAI, Rheumatoid Arthritis Disease Activity Index.